AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14707555 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 312
Study 11351929 — intervention group
Group type: COMPARATOR
Intervention: Procyclidine 10 mg
Number of subjects: 2
Study 11351929 — intervention group
Group type: COMPARATOR
Intervention: Procyclidine 15 mg
Number of subjects: 2
Study 11351929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 8996134 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg
Number of subjects: 32
Study 8996134 — intervention group
Group type: COMPARATOR
Intervention: Clodronate 1,500 mg
Number of subjects: 32
Study 8942149 — intervention group
Group type: EXPERIMENTAL
Intervention: ofloxacin 400 mg daily (BB)
Number of subjects: 26
Study 8942149 — intervention group
Group type: EXPERIMENTAL
Intervention: ofloxacin 800 mg daily (CC)
Number of subjects: 26
Study 8942149 — intervention group
Group type: COMPARATOR
Intervention: clofazimine 50 mg daily and 300 mg once in 4 weeks + dapsone 100 mg daily (AA)
Number of subjects: 26
Study 3605734 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (60% nitrous oxide in oxygen with 1.4% isoflurane)
Number of subjects: 98
Study 3605734 — intervention group
Group type: COMPARATOR
Intervention: Control (1.4% isoflurane in oxygen)
Number of subjects: 98
Study 29750266 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperuricemia (HUA) group
Number of subjects: 460
Study 29750266 — intervention group
Group type: COMPARATOR
Intervention: Normouricemic group
Number of subjects: 460
Study 29750266 — intervention group
Group type: EXPERIMENTAL
Intervention: HUA group (men)
Number of subjects: 460
Study 29750266 — intervention group
Group type: EXPERIMENTAL
Intervention: HUA group (women)
Number of subjects: 460
Study 26852238 — intervention group
Group type: EXPERIMENTAL
Intervention: OverMDC (mean distance to conformity) with a prescribed dose of 50Gy
Number of subjects: 97
Study 26852238 — intervention group
Group type: COMPARATOR
Intervention: 3D-CRT
Number of subjects: 97
Study 26852238 — intervention group
Group type: COMPARATOR
Intervention: IMRT
Number of subjects: 97
Study 26852238 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-planning from 3D-CRT to VMAT
Number of subjects: 97
Study 25607338 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/d pioglitazone
Number of subjects: 84
Study 25607338 — intervention group
Group type: COMPARATOR
Intervention: 1,000 mg/d metformin
Number of subjects: 84
Study 24135734 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MV combined with PrEP (tenofovir/emtricitabine)
Number of subjects: 68
Study 24135734 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MV combined with placebo
Number of subjects: 68
Study 24135734 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MV alone
Number of subjects: 68
Study 20569733 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of autologous bone marrow mononuclear cells (BMMC)
Number of subjects: 37
Study 20569733 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound substudy
Number of subjects: 37
Study 19077833 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Soothing Environment (OSE)
Number of subjects: 50
Study 19077833 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 50
Study 16608559 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-oriented psychological therapy (BPT)
Number of subjects: 45
Study 16608559 — intervention group
Group type: COMPARATOR
Intervention: Supportive counseling (SC)
Number of subjects: 45
Study 11918829 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg acetaminophen (paracetamol) 6 times daily for 5 days
Number of subjects: 75
Study 11918829 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen 6 times daily for 5 days
Number of subjects: 75
Study 11918829 — intervention group
Group type: COMPARATOR
Intervention: Placebo 6 times daily for 5 days
Number of subjects: 75
Study 10593430 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin once daily (mean 4631 IU anti-factor Xa units/day)
Number of subjects: 105
Study 10593430 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin twice daily (mean 20569 IU/day)
Number of subjects: 105
Study 8943981 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-chain fatty acid mixture
Number of subjects: 47
Study 8943981 — intervention group
Group type: EXPERIMENTAL
Intervention: Butyrate alone
Number of subjects: 47
Study 8943981 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 47
Study 1755884 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml 0.5% bupivacaine with adrenaline
Number of subjects: 40
Study 1755884 — intervention group
Group type: COMPARATOR
Intervention: 10 ml placebo
Number of subjects: 40
Study 6612389 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg intravenous lidocaine
Number of subjects: 16
Study 6612389 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg topical lidocaine
Number of subjects: 16
Study 29241943 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 2973
Study 29241943 — intervention group
Group type: COMPARATOR
Intervention: Women
Number of subjects: 2973
Study 27406242 — intervention group
Group type: EXPERIMENTAL
Intervention: TIME intervention (multicomponent program including rigorous assessment, case conferences, treatment and evaluation of NPS)
Number of subjects: 168
Study 27406242 — intervention group
Group type: COMPARATOR
Intervention: Brief education-only intervention regarding dementia and NPS (control group)
Number of subjects: 168
Study 24733235 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (VAR; 1 mg twice daily) + Low dose naltrexone (L-NTX; 25 mg once daily)
Number of subjects: 130
Study 24733235 — intervention group
Group type: COMPARATOR
Intervention: Varenicline (VAR; 1 mg twice daily)
Number of subjects: 130
Study 24733235 — intervention group
Group type: COMPARATOR
Intervention: Low dose naltrexone (L-NTX; 25 mg once daily)
Number of subjects: 130
Study 24733235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 23113779 — intervention group
Group type: EXPERIMENTAL
Intervention: WCP (Weight Concerns Program)
Number of subjects: 2000
Study 23113779 — intervention group
Group type: COMPARATOR
Intervention: STD (Standard Quitline)
Number of subjects: 2000
Study 19735607 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text messages prompting
Number of subjects: 62
Study 19735607 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 62
Study 18578967 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF inhibitors
Number of subjects: 0
Study 18578967 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of TNF inhibitors and methotrexate
Number of subjects: 0
Study 18578967 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 0
Study 15914522 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 19
Study 15914522 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy nondiabetic children)
Number of subjects: 19
Study 12872395 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (TCM) for activating blood circulation to remove stasis, treated for 3 months
Number of subjects: 49
Study 12872395 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment, treated for 3 months
Number of subjects: 49
Study 11012950 — intervention group
Group type: COMPARATOR
Intervention: Conventional verbal information from an ENT nurse
Number of subjects: 160
Study 11012950 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific information including role-play from a nurse anaesthetist
Number of subjects: 160
Study 8774016 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimulation (viewing high-action videotape of human stunts)
Number of subjects: 24
Study 8774016 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimulation
Number of subjects: 24
Study 8774016 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimulation (listening to fast upbeat music)
Number of subjects: 24
Study 8774016 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory/visual stimulation (both stimulations)
Number of subjects: 24
Study 8774016 — intervention group
Group type: COMPARATOR
Intervention: Control (no stimulation)
Number of subjects: 24
Study 1729934 — intervention group
Group type: EXPERIMENTAL
Intervention: Train-of-four (TOF) stimulation at 10 mA above T4 threshold
Number of subjects: 31
Study 1729934 — intervention group
Group type: EXPERIMENTAL
Intervention: Train-of-four (TOF) stimulation at various currents (10, 15, 20, 30, 40, 50, and 60 mA)
Number of subjects: 31
Study 6330643 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.8 mg in 2 ml vehicle each)
Number of subjects: 12
Study 6330643 — intervention group
Group type: COMPARATOR
Intervention: Saline (2 ml)
Number of subjects: 12
Study 30539266 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 200 mg
Number of subjects: 12
Study 30539266 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 300 mg
Number of subjects: 12
Study 30539266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29194531 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative surgery (shaving or disc excision)
Number of subjects: 60
Study 29194531 — intervention group
Group type: COMPARATOR
Intervention: Radical rectal surgery (segmental resection)
Number of subjects: 60
Study 29194531 — intervention group
Group type: COMPARATOR
Intervention: Conservative surgery and Radical rectal surgery
Number of subjects: 60
Study 25934317 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 30
Study 25934317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 24136379 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg intravenously 2 to 3 hours prior to surgery (Group A)
Number of subjects: 108
Study 24136379 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 108
Study 22738085 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.42 (Tetraspan)
Number of subjects: 798
Study 22738085 — intervention group
Group type: COMPARATOR
Intervention: Ringer's acetate
Number of subjects: 798
Study 20855843 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV
Number of subjects: 447
Study 20855843 — intervention group
Group type: COMPARATOR
Intervention: TMZ-5 (200 mg/m2 for 5 days)
Number of subjects: 447
Study 20855843 — intervention group
Group type: COMPARATOR
Intervention: TMZ-21 (100 mg/m2 for 21 days)
Number of subjects: 447
Study 20855843 — intervention group
Group type: COMPARATOR
Intervention: TMZ-5
Number of subjects: 447
Study 18276076 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful stimuli
Number of subjects: 14
Study 18276076 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-painful stimuli
Number of subjects: 14
Study 18276076 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-painful stimuli)
Number of subjects: 14
Study 18276076 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain thresholds
Number of subjects: 14
Study 18276076 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional bias to stimuli
Number of subjects: 14
Study 15680454 — intervention group
Group type: EXPERIMENTAL
Intervention: New cell-cultured smallpox vaccine (CCSV)
Number of subjects: 350
Study 15680454 — intervention group
Group type: COMPARATOR
Intervention: Calf-lymph derived vaccine (control)
Number of subjects: 350
Study 12846615 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose bupivacaine 4 mg with 25 micro g of fentanyl
Number of subjects: 2
Study 12846615 — intervention group
Group type: COMPARATOR
Intervention: 0.5% plain bupivacaine 7.5 mg
Number of subjects: 2
Study 10665784 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment in 10 fractions (total dose of 45 Gy)
Number of subjects: 335
Study 10665784 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment in 28 fractions
Number of subjects: 335
Study 10665784 — intervention group
Group type: COMPARATOR
Intervention: Air treatment in 10 fractions (total dose of 40 Gy)
Number of subjects: 335
Study 10665784 — intervention group
Group type: COMPARATOR
Intervention: Air treatment in 28 fractions
Number of subjects: 335
Study 8887208 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal isokinetic eccentric exercise (100 maximal eccentric activations of the knee extensors at 0.52 rad s‐1)
Number of subjects: 10
Study 8887208 — intervention group
Group type: COMPARATOR
Intervention: Downhill run (5 bouts of 8 min at -10% gradient at 80% predicted maximal heart rate) without prior isokinetic session
Number of subjects: 10
Study 1796125 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg N-desmethyladinazolam
Number of subjects: 15
Study 1796125 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg N-desmethyladinazolam
Number of subjects: 15
Study 1796125 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg N-desmethyladinazolam
Number of subjects: 15
Study 1796125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1796125 — intervention group
Group type: EXPERIMENTAL
Intervention: N-desmethyladinazolam (all doses)
Number of subjects: 15
Study 6366027 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy with a mixture of three grass pollen-aqueous extracts (velvet, sweet vernal, and timothy)
Number of subjects: 15
Study 6366027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31677701 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged elemental diet (ED) therapy
Number of subjects: 39
Study 31677701 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 39
Study 29343173 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic feedback with mean End-of-Life in Dementia-scores
Number of subjects: 668
Study 29343173 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific feedback with individual End-of-Life in Dementia-scores
Number of subjects: 668
Study 29343173 — intervention group
Group type: COMPARATOR
Intervention: No feedback provided
Number of subjects: 668
Study 26772739 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom made insoles by a podiatrist
Number of subjects: 185
Study 26772739 — intervention group
Group type: COMPARATOR
Intervention: Placebo insoles
Number of subjects: 185
Study 26772739 — intervention group
Group type: COMPARATOR
Intervention: Usual care by the general practitioner or sports physician
Number of subjects: 185
Study 24533512 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills treatment based on Cognitive Behaviour Therapy principles
Number of subjects: 0
Study 24533512 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 0
Study 22990651 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartiles of vitamin D binding protein (DBP)
Number of subjects: 250
Study 22990651 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D (25(OH)D) quartiles
Number of subjects: 250
Study 22990651 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D quartiles stratified by DBP (median split)
Number of subjects: 250
Study 20660552 — intervention group
Group type: EXPERIMENTAL
Intervention: RUSFs (ready‐to‐use supplementary foods)
Number of subjects: 1645
Study 20660552 — intervention group
Group type: COMPARATOR
Intervention: RUTFs (ready‐to‐use therapeutic foods)
Number of subjects: 1645
Study 16956743 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured 6-week neuropsychological course
Number of subjects: 69
Study 16956743 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 69
Study 17608739 — intervention group
Group type: EXPERIMENTAL
Intervention: BioOss (N=10; BG)
Number of subjects: 30
Study 17608739 — intervention group
Group type: EXPERIMENTAL
Intervention: BioOss and resorbable collagen membrane (N=10; BG+M)
Number of subjects: 30
Study 17608739 — intervention group
Group type: COMPARATOR
Intervention: No graft (N=10; control)
Number of subjects: 30
Study 17608739 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccally positioned implants
Number of subjects: 30
Study 17608739 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingually positioned implants
Number of subjects: 30
Study 15215086 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg/kg every 12 h for 3 doses and then 15 mg/kg every 48 h for 4 doses (daily dosing)
Number of subjects: 24
Study 15215086 — intervention group
Group type: COMPARATOR
Intervention: 6 mg/kg every 12 h for 2 doses and then 6 mg/kg every 24 h for 9 doses (alternate-day dosing)
Number of subjects: 24
Study 11408300 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural intervention
Number of subjects: 343
Study 11408300 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 343
Study 9237963 — intervention group
Group type: EXPERIMENTAL
Intervention: Olestra 32 g
Number of subjects: 68
Study 9237963 — intervention group
Group type: COMPARATOR
Intervention: Olestra 0 g (placebo)
Number of subjects: 68
Study 9237963 — intervention group
Group type: EXPERIMENTAL
Intervention: Olestra 8 g
Number of subjects: 68
Study 9237963 — intervention group
Group type: EXPERIMENTAL
Intervention: Olestra 20 g
Number of subjects: 68
Study 8505632 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (150 mg or 300 mg daily depending on concomitant AEDs)
Number of subjects: 41
Study 8505632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 8505632 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 41
Study 3321875 — intervention group
Group type: COMPARATOR
Intervention: 0.00% oxygen
Number of subjects: 10
Study 3321875 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.01% oxygen
Number of subjects: 10
Study 3321875 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.65% oxygen
Number of subjects: 10
Study 3321875 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.13% oxygen
Number of subjects: 10
Study 3321875 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.3% oxygen
Number of subjects: 10
Study 30019170 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate functional loading of short implants (6 mm)
Number of subjects: 63
Study 30019170 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading of short implants (6 mm)
Number of subjects: 63
Study 30019170 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate and delayed loading of short implants (6 mm)
Number of subjects: 63
Study 28758312 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interviews (T)
Number of subjects: 323
Study 28758312 — intervention group
Group type: COMPARATOR
Intervention: Postal surveys (P)
Number of subjects: 323
Study 28758312 — intervention group
Group type: EXPERIMENTAL
Intervention: Both assessment modes
Number of subjects: 323
Study 28758312 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups without a switch in assessment mode
Number of subjects: 323
Study 28758312 — intervention group
Group type: COMPARATOR
Intervention: Groups with a switch in assessment mode
Number of subjects: 323
Study 25757810 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic hysterectomy
Number of subjects: 256
Study 25757810 — intervention group
Group type: COMPARATOR
Intervention: Multiport laparoscopic hysterectomy
Number of subjects: 256
Study 23380039 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake norm (believing previous participants ate a lot of cookies)
Number of subjects: 64
Study 23380039 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intake norm (believing previous participants ate few cookies)
Number of subjects: 64
Study 23380039 — intervention group
Group type: COMPARATOR
Intervention: No norm control condition
Number of subjects: 64
Study 21206443 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (up to 40 mg/d)
Number of subjects: 40
Study 21206443 — intervention group
Group type: COMPARATOR
Intervention: Citalopram (up to 40 mg/d)
Number of subjects: 40
Study 19705007 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanitation campaign combining shaming and subsidies
Number of subjects: 1050
Study 19705007 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1050
Study 17237474 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal CA15-3 (>30 U/ml or >50% higher than the first value recorded)
Number of subjects: 3953
Study 17237474 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal ALP (normal, abnormal, or equivocal)
Number of subjects: 3953
Study 17237474 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CA15-3 and ALP abnormal
Number of subjects: 3953
Study 15298531 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted programs for CHF management including participation of multiple health care professionals, patient and physician education, intensive drug therapy, lifestyle modifications, and close patient monitoring.
Number of subjects: 20
Study 15298531 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic outpatient management programs for hypertension and hyperlipidemia-CAD focusing on self-management skills and regular follow-up.
Number of subjects: 20
Study 15298531 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management and physician education for CHF management.
Number of subjects: 20
Study 15298531 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-managed clinics and automated provider notices for hypertension and hyperlipidemia-CAD management.
Number of subjects: 20
Study 11910298 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring (ABPM)
Number of subjects: 6083
Study 11910298 — intervention group
Group type: COMPARATOR
Intervention: Clinic BP
Number of subjects: 6083
Study 9689369 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week isotonic resistance training program using Theraband elastic tubing and lightweight dumbbells
Number of subjects: 22
Study 9689369 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 8607111 — intervention group
Group type: EXPERIMENTAL
Intervention: Calciparine (5,000 IU prophylactic, 12,500 IU curative)
Number of subjects: 17
Study 8607111 — intervention group
Group type: EXPERIMENTAL
Intervention: Fraxiparine (3,075 IU prophylactic, 6,150 IU curative)
Number of subjects: 17
Study 8607111 — intervention group
Group type: EXPERIMENTAL
Intervention: Fraxiparine
Number of subjects: 17
Study 8607111 — intervention group
Group type: EXPERIMENTAL
Intervention: Calciparine
Number of subjects: 17